Feladilimab
- Generic Name
- Feladilimab
- Drug Type
- Biotech
- Unique Ingredient Identifier
- OUP4QB2A3R
- Background
Feladilimab is under investigation in clinical trial NCT04128696 (Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma).
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT06790303
- Locations
- π«π·
GSK Investigational Site, Bordeaux, France
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT05553808
- Locations
- πΈπͺ
GSK Investigational Site, Uppsala, Sweden
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3
Terminated
- Conditions
- Neoplasms, Head and Neck
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 117
- Registration Number
- NCT04428333
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3
Terminated
- Conditions
- Neoplasms, Head and Neck
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 315
- Registration Number
- NCT04128696
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 2
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT04126200
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT03739710
- Locations
- πΈπͺ
GSK Investigational Site, Uppsala, Sweden
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03693612
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT03447314
- Locations
- πͺπΈ
GSK Investigational Site, Barcelona, Spain
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 829
- Registration Number
- NCT02723955
- Locations
- πͺπΈ
GSK Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath